This Article Abstract Full Text (PDF) All Versions of this Article: 88/8/774    most recent hh0801.090441v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chrissobolis, S. Articles by Sobey, C. G. Search for Related Content PubMed PubMed Citation Articles by Chrissobolis, S. Articles by Sobey, C. G. Related Collections Cerebrovascular disease/stroke Animal models of human disease

(Circulation Research. 2001;88:774.)
© 2001 American Heart Association, Inc.

Molecular Medicine

Evidence That Rho-Kinase Activity Contributes to Cerebral Vascular Tone In Vivo and Is Enhanced During Chronic Hypertension

Comparison With Protein Kinase C

Sophocles Chrissobolis, Christopher G. Sobey

From the Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia.

Correspondence to Christopher G. Sobey, PhD, Department of Pharmacology, The University of Melbourne, Grattan St, Parkville, Victoria 3010, Australia. E-mail cgsobey{at}unimelb.edu.au

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—The small G protein Rho and its target Rho-kinase may participate in the mechanisms underlying vascular contractile tone via inhibition of myosin light chain phosphatase. The present study has tested the hypothesis that Rho-kinase activity normally contributes to cerebral vascular tone in vivo, and that this effect is augmented during chronic hypertension. Comparative studies also examined the role of protein kinase C (PKC) in regulation of cerebral artery tone. Two Rho-kinase inhibitors, Y-27632 (0.1 to 100 µmol/L) and HA1077 (1 to 10 µmol/L), caused marked concentration-dependent increases in basilar artery diameter of anesthetized normotensive rats (Sprague-Dawley and Wistar-Kyoto [WKY] strains), as measured using a cranial window approach. By comparison, the selective PKC inhibitors calphostin C (0.01 to 0.5 µmol/L) and Ro 31-8220 (5 µmol/L) had little or no effect on basilar artery diameter. Vasodilator responses to Y-27632 were unaffected by PKC inhibition or activation. In two models of chronic hypertension (spontaneously hypertensive rats and WKY rats treated with N-nitro-L-arginine methyl ester for 4 weeks), Y-27632 elicited cerebral vasodilator responses that were significantly greater than in control WKY rats (P<0.05), indicating that the chronically hypertensive state and not genetic factors contributed to the increased responses to Rho-kinase inhibition. PKC inhibition had no significant effect on basilar artery diameter in chronically hypertensive rats. These data suggest that Rho-kinase, but not PKC, activity contributes substantially to cerebral artery tone in vivo, and this effect is augmented in the cerebral circulation during chronic hypertension.

Key Words: cerebral artery • hypertension • protein kinase C • Rho-kinase

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Amajor determinant of vascular tone is the degree of phosphorylation of myosin light chain (MLC) in vascular muscle. This process can be enhanced in the presence of even low intracellular Ca²⁺ concentrations, such as under basal conditions in vivo, through inhibition of MLC-phosphatase (ie, Ca²⁺ sensitization). It is now recognized that the small G protein Rho and its target Rho-kinase can participate in this mechanism of vascular contraction by inhibiting MLC-phosphatase.¹ A rapidly accumulating body of literature now documents the important role of the Rho/Rho-kinase–MLC-phosphatase inhibition pathway in a variety of vascular and nonvascular cell types.²

Rho is known to be activated by numerous trimeric G proteins, and Rho/Rho-kinase is therefore expected to play a fundamental role in vascular signal transduction during responses to vasoconstrictor agonists² and also stretch.³ The use of bacterial exotoxin C3, which deactivates Rho, provided recent indirect evidence that activation of Rho (and thus potentially Rho-kinase) modulates Ca²⁺ sensitivity in permeabilized cerebral arteries in vitro,⁴ but the role of Rho-kinase in regulating intact cerebral vessel tone in vivo is not known, nor are effects of cerebrovascular disease states on Rho-kinase function.

Chronic hypertension, a major risk factor for stroke, is reportedly associated with increased myogenic tone of cerebral⁵ and noncerebral^{6 7} arteries. Significant functional changes develop in cerebral arteries during hypertension, including enhanced constriction and impaired dilatation,⁸ and are accompanied by structural changes (hypertrophy and remodeling) within the vascular wall.⁹ Because Rho-kinase may participate in both hypertrophy/reorganization of actin cytoskeleton¹⁰ and enhanced vascular tone,¹¹ increased Rho-kinase activity could contribute significantly to the structural and functional changes in cerebral arteries during hypertension. The present study has tested the hypothesis that Rho-kinase function normally plays an important role in regulating cerebrovascular tone in vivo, and that this contribution is increased in two models of chronic hypertension. For comparison, we have also examined the role of protein kinase C (PKC), another kinase proposed to be involved in Ca²⁺ sensitization and regulation of cerebral vascular tone.^{12 13}

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Procedures used in these experiments were approved by the University of Melbourne Animal Experimentation Ethics Committee. Experiments were performed in 3- to 6-month-old male Sprague-Dawley rats (SD, 432±14 g, n=42), 5- to 12-month-old male Wistar Kyoto (WKY, 432±7 g, n=20), and spontaneously hypertensive rats (SHR, 436±11 g, n=10) (Animal Resource Centre, Western Australia).

Experimental Protocol
Rats were anesthetized with pentobarbital sodium (50 mg/kg IP) supplemented at 10 to 20 mg · kg^–1 · h^–1 IV. A tracheostomy was performed for mechanical ventilation with room air and supplemental oxygen. A femoral artery catheter was used to measure arterial pressure and to obtain arterial blood, and a femoral vein was cannulated for injection of supplemental anesthetic. Arterial blood gases and pH were maintained at normal levels for the duration of the experiment (pH 7.36±0.01; PCO₂=37±1 mm Hg; PO₂=169±5 mm Hg). Body temperature was monitored continuously using a rectal probe and was maintained at 37°C to 38°C with a heating pad. The rat was then placed in a head holder in a supine position. The larynx and esophagus were retracted rostrally and laterally and the musculature covering the basioccipital bone removed. A craniotomy was then performed over the ventral brain stem and the dura and arachnoid were incised to expose the basilar artery. The cranial window was superfused at 3 mL/min with artificial cerebrospinal fluid (CSF; composition [mmol/L]: Na⁺ 154.8, Cl^– 136.1, HCO₃^– 22.9, K⁺ 2.95, Ca²⁺ 1.71, Mg²⁺ 0.65, and D-glucose 3.69) at 37°C to 38°C. When sampled from the cranial window, CSF gases and pH were as follows: pH 7.38±0.01, PCO₂=35±1 mm Hg, and PO₂=125±3 mm Hg. Diameter of the basilar artery was monitored using a microscope equipped with a TV camera coupled to a video monitor and was continuously measured using a computer-based tracking program (Diamtrak).

Studies in SD Rats
The basilar artery was allowed to stabilize for 30 minutes after the preparation of the cranial window before responses were obtained to topical application of vasoactive agents. The following drugs were tested: Y-27632 (1 to 100 µmol/L) and HA1077 (1 to 10 µmol/L)—both Rho-kinase inhibitors; phorbol 12,13-dibutyrate (0.1 µmol/L)—a PKC activator; calphostin C (0.01 to 0.5 µmol/L) and Ro 31-8220 (5 µmol/L)—both PKC inhibitors; acetylcholine (1 to 10 µmol/L)—an endothelium-dependent vasodilator; and sodium nitroprusside (0.01 to 1 µmol/L)—a nitric oxide donor. Drugs, diluted in artificial CSF, were then superfused over the cranial window in cumulatively increasing concentrations. Diameter of the basilar artery was recorded under basal conditions and when vessel diameter was stable during application of each agonist. After vessel diameter had returned to the control level, an additional 15- to 30-minute recovery period was allowed before application of another drug. The sequence of application of drugs was randomized. No more than 4 vasoactive agents were tested in each animal.

Effectiveness of the PKC inhibitors calphostin C (0.1 µmol/L, n=6) or Ro 31-8220 (n=5) was evaluated by testing the basilar artery response to the PKC activator phorbol 12,13-dibutyrate (0.1 µmol/L) after a 20-minute pretreatment with the inhibitor. The possibility that PKC activation or inhibition affects the vasodilator responses of the basilar artery to Rho-kinase inhibition was examined in rats in which responses to Y-27632 (1 µmol/L) were recorded in the presence of phorbol 12,13-dibutyrate (0.1 µmol/L, n=5) or Ro 31-8220 (5 µmol/L, n=5), respectively. For comparison, control responses to phorbol 12,13-dibutyrate (n=12) or Y-27632 (1 µmol/L, n=16) were measured in separate groups of rats. A relatively low concentration of Y-27632 (1 µmol/L) was chosen for these studies to utilize the high selectivity of this compound for inhibition of Rho-kinase versus PKC.^{2 11 14}

Studies in WKY and SHR Rats
Responses to Y-27632, calphostin C, sodium nitroprusside, and acetylcholine were compared in WKY and SHR. The main purpose of these experiments was to determine whether vasodilator responses to Y-27632 and calphostin C were altered during chronic hypertension.

Studies in N-Nitro-L-Arginine Methyl Ester–Treated WKY Rats
WKY rats (n=6) were treated for 4 weeks with N-nitro-L-arginine methyl ester (L-NAME) in their drinking water (50 mg L-NAME/100 mL). This dose of L-NAME equated to 30 mg/kg per day. On the day of experimentation, concentration-dependent vasodilator responses to Y-27632 and acetylcholine were tested. The purpose of these experiments was to determine whether vasodilator responses to Y-27632 were altered in a second nongenetic model of chronic hypertension.

Drugs
Acetylcholine chloride, sodium nitroprusside, and L-NAME were obtained from Sigma Chemical Co. HA1077 (1-[5-isoquinolenesulfonyl]-homopiperazine), calphostin C, Ro 31-8220, and phorbol 12,13-dibutyrate were obtained from Calbiochem. Y-27632 (R-[+]-trans-N-[4-pyridyl]-4-[1-aminoethyl]-cyclohexanecarboxamide) was generously provided by the Pharmaceutical Research Division, Welfide Corporation (Osaka, Japan). Calphostin C, Ro 31-8220, and phorbol 12,13-dibutyrate were dissolved in DMSO and diluted in saline. All other drugs were dissolved and diluted in saline. At the final concentration used, DMSO alone (<0.5%) had no effect on basilar artery diameter.

Statistics
Vascular responses are presented as percent change in diameter of the basilar artery compared with baseline. Data are expressed as mean±SE. Comparisons were made using Student’s paired or unpaired t tests or ANOVA, as appropriate. A value of P<0.05 was considered significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
SD Rats
In SD rats, arterial blood pressure averaged 125±2 mm Hg (n=42). Basilar artery diameter averaged 214±5 µm (n=42) under control conditions. Arterial pressure was not affected by application of any vasoactive substance to the cranial window (data not shown).

Effect of Rho-Kinase Inhibitors on Basilar Artery Diameter
Application of Y-27632 (1 to 100 µmol/L) to the cranial window caused marked concentration-dependent increases in basilar artery diameter (Figures 1A and 1B). In a separate group of rats, HA1077 (1 to 10 µmol/L) elicited cerebral vasodilator responses with a potency similar to that of Y-27632 (Figure 1B).

View larger version (17K): [in this window] [in a new window]   Figure 1. Change in basilar artery diameter of SD rats in response to cumulative application of Rho-kinase inhibitors. A, Original recording showing the time course of responses to Y-27632. B, Group concentration-response data for Y-27632 (n=3 to 7, baseline diameter=205±9 µm) and HA1077 (n=6, baseline diameter=195±10 µm). Values are mean±SE.

Effects of PKC
Neither of the PKC inhibitors studied, calphostin C or Ro 31-8220, had a substantial effect on basilar artery diameter. Three concentrations of calphostin C (0.01, 0.1, and 0.5 µmol/L) had the following effects on basilar artery diameter: 2±1% (n=8), 10±6% (n=12), and 0±3% (n=3), respectively. Effects of calphostin C (0.1 µmol/L) and Ro 31-8220 (5 µmol/L) are shown in Figure 2A. Both inhibitors virtually abolished vasoconstrictor responses to the PKC activator phorbol 12,13-dibutyrate (0.1 µmol/L; Figure 2B), confirming that PKC activity was effectively inhibited by both agents. Further, vasodilator responses to Y-27632 were unaffected by either PKC activation or inhibition (Figure 2C).

View larger version (13K): [in this window] [in a new window]   Figure 2. A, Change in basilar artery diameter of SD rats in response to the PKC inhibitors calphostin C (0.1 µmol/L, n=12, baseline diameter=206±13 µm) or Ro 31-8220 (5 µmol/L, n=5, baseline diameter=230±9 µm). B, Constrictor effect of phorbol 12,13-dibutyrate (PdB) on the basilar artery in control rats (n=12, baseline diameter=223±10 µm) and in rats pretreated with calphostin C (n=6, baseline diameter=276±24 µm) or Ro 31-8220 (n=5, baseline diameter=222±7 µm). *P<0.05 vs control PdB response. C, Effect of Y-27632 (1 µmol/L) on basilar artery diameter in control rats (open bar, n=16, baseline diameter=211±10 µm) or in rats pretreated with PdB (solid bar, n=5, baseline diameter=154±6 µm) or Ro 31-8220 (striped bar, n=5, baseline diameter=215±12 µm). Values are mean±SE.

WKY and SHR Rats
Arterial blood pressure averaged 109±6 mm Hg in WKY (n=14) and 189±4 mm Hg in SHR (n=10; P<0.05 versus WKY). Baseline basilar artery diameter was slightly greater in WKY (242±7 µm) compared with SHR (216±7 µm; P<0.05).

Y-27632 elicited dilator responses of the basilar artery that were greater in SHR versus WKY (P<0.05; Figure 3A). In contrast, calphostin C had no significant effect on basilar artery diameter in either WKY or SHR (Figure 3B). Furthermore, vasodilator responses to sodium nitroprusside were similar in WKY and SHR (Figure 3C), whereas responses to acetylcholine were reduced in SHR (Figure 3D), reflecting normal responsiveness of cerebral vascular muscle but dysfunction of endothelium, respectively, during chronic hypertension.

View larger version (13K): [in this window] [in a new window]   Figure 3. Changes in basilar artery diameter of WKY and SHR rats in response to Y-27632 (A) (WKY: n=6, baseline diameter=235±12 µm; SHR: n=6, baseline diameter=208±6 µm), calphostin C (B) (0.1 µmol/L; WKY: n=5, baseline diameter=242±10 µm; SHR: n=4, baseline diameter=223±8 µm), sodium nitroprusside (C) (SNP; WKY: n=11, baseline diameter=241±10 µm; SHR: n=9, baseline diameter=222±6 µm), and acetylcholine (D) (ACh; WKY: n=13, baseline diameter=233±7 µm; SHR: n=15, baseline diameter=207±6 µm). Values are mean±SE. *P<0.05 vs WKY.

L-NAME–Treated WKY Rats
Arterial blood pressure averaged 147±6 mm Hg in L-NAME–treated WKY (P<0.05 versus control WKY). Baseline diameter of the basilar artery averaged 212±15 µm in L-NAME–treated WKY rats (P<0.05 versus control WKY diameter). Y-27632 elicited cerebral vasodilator responses in L-NAME–treated WKY that were greater than responses recorded in control WKY rats (Figure 4A). By contrast, responses to acetylcholine were reduced (at 1 µmol/L; P<0.05 versus control WKY) or preserved (at 10 µmol/L; P>0.05) in L-NAME–treated versus control WKY rats (Figure 4B).

View larger version (19K): [in this window] [in a new window]   Figure 4. Changes in basilar artery diameter of control WKY and L-NAME–treated WKY rats in response to Y-27632 (A) (control WKY: n=6, baseline diameter=235±12 µm; L-NAME–treated WKY: n=6, baseline diameter=212±15 µm) and acetylcholine (B) (ACh; control WKY: n=13, baseline diameter=233±7 µm; L-NAME–treated WKY: n=6, baseline diameter=212±15 µm). Values are mean±SE. *P<0.05 vs control WKY.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The results of the present study indicate that Rho-kinase plays a substantial role in increasing the tone of cerebral arteries, both in normal and hypertensive rats. The major findings were, first, that Y-27632 and HA1077, two pharmacological inhibitors of Rho-kinase, each produced profound dilatation of the basilar artery of normotensive rats. This suggests that Rho-kinase is present and functionally important in contributing to normal resting tone of the cerebral circulation in vivo. Second, cerebral vasodilator responses to Y-27632 were selectively augmented in either genetic or experimentally induced models of hypertension. This finding is consistent with the concept that chronic hypertension leads to increased Rho-kinase function in the cerebral circulation. Third, by contrast, two selective inhibitors of PKC had little or no effect on basilar artery diameter of either normotensive or hypertensive rats, suggesting that PKC activity plays no more than a modest role in regulation of resting diameter of the basilar artery. Fourth, the vasodilator response to Y-27632 was not affected by either pharmacological activation or inhibition of PKC, suggesting that cerebral vascular effects of Rho-kinase activity are independent of, and unaffected by, PKC activity.

Rho-Kinase Function in Blood Vessels
Because Rho is known to be activated by numerous trimeric G proteins, the Rho/Rho-kinase mechanism of Ca²⁺ sensitization is expected to play a fundamental role in signal transduction during responses to vasoconstrictor agonists.^{2 15} Further, the basal contractile state of cerebral arteries in vivo occurs largely as a response to the intravascular blood pressure,¹³ and it is now known that Rho can be strongly activated by stretch in vascular muscle cells.³ Thus, the combined effects of endogenous vasoconstrictor agonists and intravascular pressure in vivo could represent important stimuli for significant Rho-kinase activity in the normal regulation of vascular tone. The present experiments are the first to investigate the function of Rho-kinase in normal or hypertensive cerebral arteries in vivo. As expected, Western blotting confirmed that Rho-kinase (160 kDa), a ubiquitously expressed enzyme, is present in the rat basilar artery (data not shown). Our finding that topical application of two structurally unrelated Rho-kinase inhibitors, Y-27632 and HA1077, to the basilar artery of anesthetized normotensive (SD and WKY) rats produces marked concentration-dependent vasodilatation is consistent with the concept that Rho-kinase activity plays an important role in physiological regulation of cerebral vascular tone in vivo. Nevertheless, it is acknowledged that despite the precautions taken to maintain animals under controlled conditions throughout each experiment, we cannot exclude the possibility that induction of anesthesia, preparation of craniotomy, and other operative and perioperative procedures could potentially increase Rho-kinase activity above levels normally present in an ambulatory animal.

Selectivity of Rho-Kinase Inhibitors
The novel cell-permeant pyridine derivative, Y-27632, is described as a highly selective Rho-kinase inhibitor.^{2 11 14} In comparison to its inhibitory effect on Rho-kinase, the potency of Y-27632 is >200-fold lower as a PKC inhibitor and >1700-fold lower as an MLC-kinase inhibitor.¹¹ In the concentration range of 0.3 to 100 µmol/L, Y-27632 is reported to cause profound relaxation of receptor agonist–contracted vascular rings through inhibition of Rho-kinase.¹¹ It therefore seems likely that the vasodilator effects of similar concentrations of Y-27632 observed in the present study were also related to inhibition of Rho-kinase in basilar artery smooth muscle cells. HA1077, also named fasudil, is a vasodilator known to possess several mechanisms of action including inhibition of PKC,¹⁶ although it is now known to be 30-fold more potent as a Rho-kinase inhibitor.^{11 14} Of particular relevance to our study is that Y-27632 and HA1077 are reported to have similar potencies as Rho-kinase inhibitors in in vitro assays of enzyme activity and of Ca²⁺ sensitization–induced contraction of intestinal smooth muscle.^{11 14} We also observed remarkably similar potencies of Y-27632 and HA1077 in producing dilatation of the basilar artery (Figure 1B), consistent with the proposal that these effects were due to inhibition of Rho-kinase.

Effect of Hypertension on Rho-Kinase Function in the Cerebral Circulation
Pathological conditions involving an increased level of myogenic tone in cerebral vessels may potentially compromise brain blood flow and contribute to cerebral ischemia and stroke. Chronic hypertension, a major risk factor for stroke, is reportedly associated with increased myogenic tone of cerebral⁵ and noncerebral^{6 7} arteries. An augmented hypotensive effect of intravenous Y-27632 in experimental hypertension has provided evidence for pathological activity of Rho-kinase in chronic hypertension.¹¹ However, the effects of hypertension on Rho-kinase function have not been reported in any specific vascular bed in vivo. Our present findings, that cerebral vasodilator responses to Y-27632 are selectively augmented in the hypertensive SHR and L-NAME–treated WKY rats in comparison to normotensive control WKY rats, indicate that chronic hypertension leads to increased Rho-kinase function in the cerebral circulation. Thus, abnormally high Rho-kinase activity in vascular smooth muscle during hypertension may not only exacerbate the increased blood pressure¹¹ but could potentially limit physiological increases in cerebral blood flow as a result of increased vascular tone. Analogous findings have recently been reported in experimental models of coronary¹⁷ and cerebral¹⁸ vasospasm, consistent with an emerging general concept that Rho-kinase activity may be abnormally elevated in blood vessels during a number of cardiovascular disease states.

We confirmed previous in vivo findings^{19 20 21 22} that in genetically hypertensive rats dilator responses of the basilar artery to acetylcholine are reduced, whereas responses to sodium nitroprusside are preserved. This phenomenon is thought to indicate impaired production and/or activity of endothelium-derived nitric oxide but normal responsiveness of the vascular muscle to nitric oxide during chronic hypertension. Similarly, in WKY rats that were chronically treated with L-NAME, vasodilator responses to acetylcholine were partially (but not fully) impaired. This finding probably indicates that endothelial nitric oxide synthase activity in the basilar artery was submaximally inhibited by the daily L-NAME dose of 30 mg/kg. Nevertheless, the L-NAME treatment regimen was clearly effective in producing elevated arterial pressure that was associated with an increased cerebral vasodilator response to Y-27632. Thus, vascular Rho-kinase activity appears to be increased as a secondary consequence of hypertension, independent of the primary mechanism contributing to the elevated pressure and of genetic mechanisms.¹¹

Role of PKC
PKC activity is potentially important in regulating basal tone and myogenic responses of cerebral arteries.^{12 13} Pharmacological activation of PKC, eg, by using phorbol esters, is known to be a powerful cerebral vasoconstrictor stimulus in vitro^{4 23 24 25} and in vivo^{26 27 28} because of increased Ca²⁺ sensitivity of vascular contractile elements. We confirmed that activation of PKC is a strong constrictor stimulus in the basilar artery, in that phorbol 12,13-dibutyrate produced marked vasoconstriction that could be blocked by pretreating the artery with either of two relatively selective PKC inhibitors, calphostin C or Ro 31-8220.

Of particular importance to our study was the finding that calphostin C and Ro 31-8220 each had only a minimal effect on baseline diameter of the basilar artery, suggesting that any normal effect of basal PKC activity on the tone of this cerebral vessel in vivo is very small and apparently much less important than Rho-kinase. Such a conclusion is conceptually consistent with recent findings in isolated and permeabilized ovine cerebral arteries, in which agonist-induced Ca²⁺ sensitization could be prevented by inactivation of Rho (using exotoxin C3) but was not affected by inhibition of PKC.⁴ Thus, although activation of PKC and Rho-kinase may both lead to increased vascular tone through Ca²⁺ sensitization, it appears that only the latter mechanism is normally active in the basilar artery under resting conditions. Moreover, the finding that calphostin C had virtually no effect on baseline diameter of the basilar artery in SHR or WKY rats suggests that the influence of PKC activity on cerebral artery tone under basal conditions in vivo remains insignificant during chronic hypertension. Because the vasodilator response to Y-27632 was not affected by PKC activation (using phorbol 12,13-dibutyrate) or inhibition (using Ro 31-8220), it appears that cerebral vascular effects of Rho-kinase are independent of, and unaffected by, PKC activity, consistent with the finding that Y-27632 does not affect PKC-induced Ca²⁺ sensitization in permeabilized pulmonary vascular smooth muscle.²⁹

Poorly selective PKC inhibitors (eg, sphingosine, H-7, staurosporine) have also been reported to have little or no effect in vivo on baseline diameter of the basilar artery^{27 30} or of cremaster muscle arterioles,³¹ in agreement with our findings using much more selective PKC inhibitors. By contrast, other investigators^{25 32} have reported that staurosporine or U-73122, a nonselective inhibitor of phospholipase C (which also inhibits voltage-operated Ca²⁺ channels with greater potency³³ ), can dilate isolated cannulated posterior cerebral arteries, and suggested that PKC activation contributes to cerebrovascular myogenic tone. Thus, the difference between those^{25 32} and the present findings could be related to the differing selectivity of inhibitors used, different vessels studied, or the in vivo versus in vitro conditions.

In summary, the findings of the present study provide the first evidence that Rho-kinase activity normally contributes to the regulation of cerebral vascular tone in vivo. Moreover, Rho-kinase–mediated contractile tone appears to be enhanced in the basilar artery in models of chronic hypertension that are either pharmacologically induced or genetic in origin. In contrast, PKC activity does not appear to contribute significantly to basilar artery tone in either normotensive or hypertensive animals. Thus, the augmented cerebrovascular Rho-kinase activity appears to be a secondary phenomenon and not a primary cause of this disease state. Nevertheless, elevated Rho-kinase activity in the vasculature may represent a harmful positive feedback mechanism that could contribute to the generalized hypertensive state by further increasing vascular resistance. Vascular Rho/Rho-kinase may represent a novel therapeutic target in clinical conditions for which hypertension is a major risk factor, such as stroke and myocardial infarction. Indeed, it has recently been noted that HMG-CoA reductase inhibitors (statins), which inhibit Rho activation as a consequence of inhibiting isoprene formation,³⁴ appear to have beneficial effects that cannot be accounted for in some patients by the level of reduction of plasma cholesterol.³⁵ Hence, inactivation of Rho/Rho-kinase function may be an important additional beneficial action of statins in the treatment of numerous cardiovascular diseases.³⁶ Further exploration of potential opportunities to target this biochemical pathway in cardiovascular therapy will be an important direction for future studies.

	Acknowledgments

 
These experiments were supported by a project grant from the National Health and Medical Research Council of Australia. We are grateful to Dr Phil Marley for helpful advice throughout this study and to the Pharmaceutical Research Division, Welfide Corporation (Osaka, Japan), for generously providing Y-27632.

	Footnotes

 
Original received November 6, 2000; revision received March 2, 2001; accepted March 21, 2001.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Regulation of myosin phosphatase by rho and rho-associated kinase (rho-kinase). Science. 1996;273:245–248.

2. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522:177–185.

3. Numaguchi K, Eguchi S, Yamakawa T, Motley ED, Inagami T. Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and intact actin filaments. Circ Res. 1999;85:5–11.

4. Akopov SE, Zhang L, Pearce WJ. Regulation of Ca²⁺ sensitization by PKC and rho proteins in ovine cerebral arteries: effects of artery size and age. Am J Physiol. 1998;275:H930–H939.

5. Harder DR, Smeda J, Lombard J. Enhanced myogenic depolarization in hypertensive cerebral arterial muscle. Circ Res. 1985;57:319–322.

6. Gebremedhin D, Fenoy FJ, Harder DR, Roman RJ. Enhanced vascular tone in the rat vasculature of spontaneously hypertensive rats. Hypertension. 1990;16:648–654.

7. Falcone JC, Granger HJ, Meininger GA. Enhanced myogenic activation in skeletal muscle arterioles from spontaneously hypertensive rats. Am J Physiol. 1993;265:H1847–H1855.

8. Faraci FM, Heistad DD. Regulation of large cerebral arteries and cerebral microvascular pressure. Circ Res. 1990;66:8–17.

9. Heistad DD, Baumbach GL, Kitazono T, Faraci FM. Effects of hypertension on cerebral blood vessels. Hypertens Res. 1993;16:225–231.

10. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH. The low molecular weight GTPase rho regulates myofibril formation and organization in neonatal rat ventricular myocytes: involvement of rho kinase. J Biol Chem. 1998;273:7725–7730.

11. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–994.

12. Osol G. Mechanotransduction by vascular smooth muscle. J Vasc Res. 1995;32:275–292.

13. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev. 1999;79:387–423.

14. Swärd K, Dreja K, Hellstrand P, Hartshorne DJ, Walsh MP. Inhibition of Rho-associated kinase blocks agonist-induced Ca²⁺ sensitization of myosin phosphorylation and force in guinea pig ileum. J Physiol. 2000;522:33–49.

15. Seasholtz TM, Majumdar M, Brown JH. Rho as a mediator of G protein-coupled receptor signaling. Mol Pharmacol. 1999;55:949–956.

16. Ono-Saito N, Niki I, Hidaka H. H-series protein kinase inhibitors and potential clinical applications. Pharmacol Ther. 1999;82:123–131.

17. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029–1039.

18. Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res. 2000;87:195–200.

19. Mayhan WG. Impairment of endothelium-dependent dilatation of basilar artery during chronic hypertension. Am J Physiol. 1990;259:H1455–H1462.

20. Kitazono T, Heistad DD, Faraci FM. ATP-sensitive potassium channels in the basilar artery during chronic hypertension. Hypertension. 1993;22:677–681.

21. Kitazono T, Heistad DD, Faraci FM. Enhanced responses of the basilar artery to activation of endothelin-B receptors in stroke-prone spontaneously hypertensive rats. Hypertension. 1995;25(pt 1):490–494.

22. Sobey CG, Moffatt JD, Cocks TM. Evidence for selective effects of chronic hypertension on cerebral artery vasodilatation to protease-activated receptor-2 activation. Stroke. 1999;30:1933–1941.

23. Salaices M, Balfagon G, Arribas S, de Sagarra MR, Marin J. Effects of phorbol 12,13-dibutyrate on the vascular tone and on norepinephrine- and potassium-induced contractions of cat cerebral arteries. J Pharmacol Exp Ther. 1990;255:66–73.

24. Sugawa M, Koide T, Naitoh S, Takato M, Matsui T, Asano T. Phorbol 12,13-diacetate-induced contraction of the canine basilar artery: role of protein kinase C. J Cereb Blood Flow Metab. 1991;11:135–142.

25. Osol G, Laher I, Cipolla M. Protein kinase C modulates basal myogenic tone in resistance arteries from the cerebral circulation. Circ Res. 1991;68:359–367.

26. Busija DW, Chen J. Reversal by increased CSF [H⁺] and [K⁺] of phorbol ester-induced arteriolar constriction in piglets. Am J Physiol. 1992;263:H1455–H1459.

27. Murray MA, Faraci FM, Heistad DD. Role of protein kinase C in constrictor responses of the rat basilar artery in vivo. J Physiol. 1992;445:169–179.

28. Murray MA, Faraci FM, Heistad DD. Signal transduction pathways in constriction of the basilar artery in vivo. Hypertension. 1992;19:739–742.

29. Fu X, Gong MC, Jia T, Somlyo AV, Somlyo AP. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPS-, and phorbol ester-induced Ca²⁺-sensitization of smooth muscle. FEBS Lett. 1998;440:183–187.

30. Murray MA, Faraci FM, Heistad DD. Effect of protein kinase C inhibitors on endothelin- and vasopressin-induced constriction of the rat basilar artery. Am J Physiol. 1992;263:H1643–H1649.

31. Hill MA, Falcone JC, Meininger GA. Evidence for protein kinase C involvement in arteriolar myogenic reactivity. Am J Physiol. 1990;259:H1586–H1594.

32. Osol G, Laher I, Kelley M. Myogenic tone is coupled to phospholipase C and G protein activation in small cerebral arteries. Am J Physiol. 1993;265:H415–H420.

33. Taylor CW, Broad LM. Pharmacological analysis of intracellular Ca²⁺ signalling: problems and pitfalls. Trends Pharmacol Sci. 1998;19:370–375.

34. Goldstein JL, Brown JS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430.

35. Packard CJ. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study. Circulation. 1998;97:1440–1445.

36. Laufs U, Liao JK. Targeting rho in cardiovascular disease. Circ Res. 2000;87:526–528.

This article has been cited by other articles:

				Y. Chiba, S. Nakazawa, M. Todoroki, K. Shinozaki, H. Sakai, and M. Misawa Interleukin-13 Augments Bronchial Smooth Muscle Contractility with an Up-Regulation of RhoA Protein Am. J. Respir. Cell Mol. Biol., February 1, 2009; 40(2): 159 - 167. [Abstract] [Full Text] [PDF]

				Y. Chiba, J. Arima, H. Sakai, and M. Misawa Lovastatin inhibits bronchial hyperresponsiveness by reducing RhoA signaling in rat allergic asthma Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L705 - L713. [Abstract] [Full Text] [PDF]

				R. L. Corteling, S. E. Brett, H. Yin, X.-L. Zheng, M. P. Walsh, and D. G. Welsh The functional consequence of RhoA knockdown by RNA interference in rat cerebral arteries Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H440 - H447. [Abstract] [Full Text] [PDF]

				A. A. Miller, G. R. Drummond, A. E. Mast, H. H.H.W. Schmidt, and C. G. Sobey Effect of Gender on NADPH-Oxidase Activity, Expression, and Function in the Cerebral Circulation: Role of Estrogen Stroke, July 1, 2007; 38(7): 2142 - 2149. [Abstract] [Full Text] [PDF]

				S. Chrissobolis and C. G. Sobey Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease Stroke, August 1, 2006; 37(8): 2174 - 2180. [Abstract] [Full Text] [PDF]

				H. Li, K. Witte, M. August, I. Brausch, U. Godtel-Armbrust, A. Habermeier, E. I. Closs, M. Oelze, T. Munzel, and U. Forstermann Reversal of Endothelial Nitric Oxide Synthase Uncoupling and Up-Regulation of Endothelial Nitric Oxide Synthase Expression Lowers Blood Pressure in Hypertensive Rats J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2536 - 2544. [Abstract] [Full Text] [PDF]

				K. Budzyn, M. Paull, P. D. Marley, and C. G. Sobey Segmental Differences in the Roles of Rho-Kinase and Protein Kinase C in Mediating Vasoconstriction J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 791 - 796. [Abstract] [Full Text] [PDF]

				T. M. Seasholtz, J. Wessel, F. Rao, B. K. Rana, S. Khandrika, B. P. Kennedy, E. O. Lillie, M. G. Ziegler, D. W. Smith, N. J. Schork, et al. Rho Kinase Polymorphism Influences Blood Pressure and Systemic Vascular Resistance in Human Twins: Role of Heredity Hypertension, May 1, 2006; 47(5): 937 - 947. [Abstract] [Full Text] [PDF]

				J. H. Brown, D. P. Del Re, and M. A. Sussman The Rac and Rho Hall of Fame: A Decade of Hypertrophic Signaling Hits Circ. Res., March 31, 2006; 98(6): 730 - 742. [Abstract] [Full Text] [PDF]

				Y. Chiba, M. Murata, H. Ushikubo, Y. Yoshikawa, A. Saitoh, H. Sakai, J. Kamei, and M. Misawa Effect of Cigarette Smoke Exposure In Vivo on Bronchial Smooth Muscle Contractility In Vitro in Rats Am. J. Respir. Cell Mol. Biol., December 1, 2005; 33(6): 574 - 581. [Abstract] [Full Text] [PDF]

				Y. P. R. Jarajapu and H. J. Knot Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1917 - H1922. [Abstract] [Full Text] [PDF]

				K. Budzyn, P. D. Marley, and C. G. Sobey Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1248 - 1253. [Abstract] [Full Text] [PDF]

				M. Rajasekaran, S. White, A. Baquir, and N. Wilkes Rho-kinase Inhibition Improves Erectile Function in Aging Male Brown-Norway Rats J Androl, March 1, 2005; 26(2): 182 - 188. [Abstract] [Full Text] [PDF]

				T. Nagaoka, K. A. Fagan, S. A. Gebb, K. G. Morris, T. Suzuki, H. Shimokawa, I. F. McMurtry, and M. Oka Inhaled Rho Kinase Inhibitors Are Potent and Selective Vasodilators in Rat Pulmonary Hypertension Am. J. Respir. Crit. Care Med., March 1, 2005; 171(5): 494 - 499. [Abstract] [Full Text] [PDF]

				G. Loirand, M. Rolli-Derkinderen, and P. Pacaud RhoA and resistance artery remodeling Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1051 - H1056. [Abstract] [Full Text] [PDF]

				S. P. Didion, C. M. Lynch, G. L. Baumbach, and F. M. Faraci Impaired Endothelium-Dependent Responses and Enhanced Influence of Rho-Kinase in Cerebral Arterioles in Type II Diabetes Stroke, February 1, 2005; 36(2): 342 - 347. [Abstract] [Full Text] [PDF]

				F. M. Faraci Oxidative Stress: The Curse That Underlies Cerebral Vascular Dysfunction? Stroke, February 1, 2005; 36(2): 186 - 188. [Full Text] [PDF]

				T. M. Seasholtz and J. H. Brown RHO SIGNALING in Vascular Diseases Mol. Interv., December 1, 2004; 4(6): 348 - 357. [Abstract] [Full Text] [PDF]

				B. Erdos, J. A. Snipes, B. Kis, A. W. Miller, and D. W. Busija Vasoconstrictor mechanisms in the cerebral circulation are unaffected by insulin resistance Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1456 - R1461. [Abstract] [Full Text] [PDF]

				D. L. Lee, R. C. Webb, and L. Jin Hypertension and RhoA/Rho-Kinase Signaling in the Vasculature: Highlights From the Recent Literature Hypertension, December 1, 2004; 44(6): 796 - 799. [Abstract] [Full Text] [PDF]

				S. Chrissobolis, K. Budzyn, P. D. Marley, and C. G. Sobey Evidence That Estrogen Suppresses Rho-Kinase Function in the Cerebral Circulation In Vivo Stroke, September 1, 2004; 35(9): 2200 - 2205. [Abstract] [Full Text] [PDF]

				K. Budzyn, P. D. Marley, and C. G. Sobey Chronic mevastatin modulates receptor-dependent vascular contraction in eNOS-deficient mice Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R342 - R348. [Abstract] [Full Text] [PDF]

				E. A. Wehrwein, C. A. Northcott, R. D. Loberg, and S. W. Watts Rho/Rho Kinase and Phosphoinositide 3-Kinase Are Parallel Pathways in the Development of Spontaneous Arterial Tone in Deoxycorticosterone Acetate-Salt Hypertension J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1011 - 1019. [Abstract] [Full Text] [PDF]

				A. P. SOMLYO and A. V. SOMLYO Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase Physiol Rev, October 1, 2003; 83(4): 1325 - 1358. [Abstract] [Full Text] [PDF]

				J. Galle, A. Mameghani, S.-S. Bolz, S. Gambaryan, M. Gorg, T. Quaschning, U. Raff, H. Barth, S. Seibold, C. Wanner, et al. Oxidized LDL and its Compound Lysophosphatidylcholine Potentiate AngII-Induced Vasoconstriction by Stimulation of RhoA J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1471 - 1479. [Abstract] [Full Text] [PDF]

				K. Hosaka, R. Mizuno, and T. Ohhashi Rho-Rho kinase pathway is involved in the regulation of myogenic tone and pump activity in isolated lymph vessels Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2015 - H2025. [Abstract] [Full Text] [PDF]

				G. Wickman, C. Lan, and B. Vollrath Functional Roles of the Rho/Rho Kinase Pathway and Protein Kinase C in the Regulation of Cerebrovascular Constriction Mediated by Hemoglobin: Relevance to Subarachnoid Hemorrhage and Vasospasm Circ. Res., April 18, 2003; 92(7): 809 - 816. [Abstract] [Full Text] [PDF]

				T. Seko, M. Ito, Y. Kureishi, R. Okamoto, N. Moriki, K. Onishi, N. Isaka, D. J. Hartshorne, and T. Nakano Activation of RhoA and Inhibition of Myosin Phosphatase as Important Components in Hypertension in Vascular Smooth Muscle Circ. Res., March 7, 2003; 92(4): 411 - 418. [Abstract] [Full Text] [PDF]

				V. Randriamboavonjy, R. Busse, and I. Fleming 20-HETE-Induced Contraction of Small Coronary Arteries Depends on the Activation of Rho-Kinase Hypertension, March 1, 2003; 41(3): 801 - 806. [Abstract] [Full Text] [PDF]

				S. Shirao, S. Kashiwagi, M. Sato, S. Miwa, F. Nakao, T. Kurokawa, N. Todoroki-Ikeda, K. Mogami, Y. Mizukami, S. Kuriyama, et al. Sphingosylphosphorylcholine Is a Novel Messenger for Rho-Kinase-Mediated Ca2+ Sensitization in the Bovine Cerebral Artery: Unimportant Role for Protein Kinase C Circ. Res., July 26, 2002; 91(2): 112 - 119. [Abstract] [Full Text] [PDF]

				K. G. Lamping Enhanced Contractile Mechanisms in Vasospasm: Is Endothelial Dysfunction the Whole Story? Circulation, April 2, 2002; 105(13): 1520 - 1522. [Full Text] [PDF]

				M. Tosaka, F. Okajima, Y. Hashiba, N. Saito, T. Nagano, T. Watanabe, T. Kimura, and T. Sasaki Sphingosine 1-Phosphate Contracts Canine Basilar Arteries In Vitro and In Vivo: Possible Role in Pathogenesis of Cerebral Vasospasm Stroke, December 1, 2001; 32(12): 2913 - 2919. [Abstract] [Full Text] [PDF]

				T. M. Seasholtz, T. Zhang, M. R. Morissette, A. L. Howes, A. H. Yang, and J. H. Brown Increased Expression and Activity of RhoA Are Associated With Increased DNA Synthesis and Reduced p27Kip1 Expression in the Vasculature of Hypertensive Rats Circ. Res., September 14, 2001; 89(6): 488 - 495. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 88/8/774    most recent hh0801.090441v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chrissobolis, S. Articles by Sobey, C. G. Search for Related Content PubMed PubMed Citation Articles by Chrissobolis, S. Articles by Sobey, C. G. Related Collections Cerebrovascular disease/stroke Animal models of human disease